1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
64690FB6C62978E53852583C8006B841E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/4690FB6C62978E53852583C8006B841E
18
19
2054.81.69.220
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Science Liaison

Optimizing the Size and Improving the Impact of Oncology Field-Based Medical Teams in Major Global Markets: Optimizing Staffing and Resources

ID: 5552


Features:

10 Info Graphics

20 Data Graphics

200+ Metrics

4 Narratives


Pages/Slides: 33


Published: 2019


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Optimizing the Size and Improving the Impact of Oncology Field-Based Medical Teams in Major Global Markets: Optimizing Staffing and Resources"

STUDY OVERVIEW

To maximize the impact of oncology-focused field-based medical teams in high-potential global markets, organizations need to have staffing and resource levels that reflect the needs and opportunities of different regions. To provide current oncology field team staffing and resource metrics in North America, Europe and globally, Best Practices, LLC conducted this study to deliver benchmarks around staffing levels, resource allocations, and favored MSL backgrounds.

This study will help companies fill knowledge gaps around key operational areas for oncology-focused field medical teams, including staffing and resourcing in high-potential geographies. Leaders involved with field-based medical teams focused on oncology can utilize this study to create a road map for becoming more effective in high-potential global markets.

This study includes four segments: All Participants, North America, Europe (Germany and UK), and global (countries outside the US).

KEY TOPICS

  • Executive Summary: Methodology, Participants, & Key Findings
  • Optimal Field Team Staffing and Resourcing

KEY METRICS
  • Total staff allocated to five roles: MSL, MSL manager, MSL effectiveness, HOL, HOL manager
  • Total MSL staff compared to total HOL staff, on average
  • On average, how many thought leaders do each of your MSLs support?
  • What percentage of thought leaders served are HCPs versus KOLs?
  • Do your field MSLs suport large key accounts (hospitals, etc.)?
  • How many large key accounts does each MSL support, on average?
  • How many payers do each of your MSLs support, on average?
  • What percentage of the peak MSL team size, on average, are assigned to support a product at each product lifecycle phase?
  • Percentage of your MSLs that have worked previously in the following roles?
  • How effective are the following backgrounds for enabling your MSLs to engage thought leaders in high quality scientific discussions
  • How many years of experience do your MSLs have, on average
SAMPLE KEY FINDINGS
  • MSL Background: MSLs are most likely to have a pharmacist background (47%). MSLs with backgrounds as a scientist (38%) or physician (31%) are also common. Just 14% of MSLs are former nurses. U.S. field-medical teams make extensive use of pharmacists (56% of all MSLs), while EU5 field teams leverage scientists and physicians more heavily.

METHODOLOGY

Overall, 20 field-based medical leaders and medical affairs executives participated in this benchmark research. These leaders provided field performance data and qualitative insights from a total of 15 Oncology pharma and biotech organizations.

Industries Profiled:
Pharmaceutical; Health Care; Biotech; Chemical; Manufacturing; Consumer Products; Diagnostic; Medical Device


Companies Profiled:
AstraZeneca; Daiichi Sankyo; Eisai; EMD Serono; Merck; Genentech; GlaxoSmithKline ; Shire; Janssen; Ipsen; Astellas; Amgen; Bayer; Roche; Merck Serono

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.